Therapeutic efficacy of lenvatinib in hepatocellular carcinoma patients with portal hypertension
Sign Up to like & getrecommendations! Published in 2020 at "Hepatology Research"
DOI: 10.1111/hepr.13537
Abstract: Preserved liver function may be an important factor affecting therapeutic efficacy in hepatocellular carcinoma patients treated with lenvatinib, but not all patients can be treated while preserving liver function. This study evaluated the therapeutic efficacy… read more here.
Keywords: hepatocellular carcinoma; therapeutic efficacy; efficacy; portal hypertension ... See more keywords
A Phase II study of the safety and efficacy of lenvatinib in patients with advanced thyroid cancer.
Sign Up to like & getrecommendations! Published in 2019 at "Future oncology"
DOI: 10.2217/fon-2018-0557
Abstract: AIM To investigate the safety and efficacy of lenvatinib in advanced thyroid cancer. PATIENTS/METHODS In this Phase II study, 51 Japanese patients with radioiodine-refractory differentiated thyroid cancer (RR-DTC), medullary thyroid cancer (MTC) or anaplastic thyroid cancer… read more here.
Keywords: cancer; efficacy lenvatinib; safety efficacy; thyroid cancer ... See more keywords
Safety and efficacy of lenvatinib combined with camrelizumab plus transcatheter arterial chemoembolization for unresectable hepatocellular carcinoma: A two-center retrospective study
Sign Up to like & getrecommendations! Published in 2022 at "Frontiers in Oncology"
DOI: 10.3389/fonc.2022.982948
Abstract: Objectives To compare the safety and efficacy of lenvatinib (LEN) combined with camrelizumab plus transcatheter arterial chemoembolization (TACE-LEN-C) and TACE combined with LEN (TACE-LEN) in patients with unresectable hepatocellular carcinoma (uHCC). Methods Eighty-three patients with… read more here.
Keywords: efficacy lenvatinib; tace; safety efficacy; combined camrelizumab ... See more keywords